Doctors called on the Centers for Disease Control and Prevention to update medical codes to include side effects suffered by ...

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...

Nation’s Report Card shows historic lows in national test scores and widening achievement gap amid federal support uncertainty.

Dianthus Therapeutics announces positive Phase II results for Claseprubart in myasthenia gravis, highlighting best-in-class potential.

U.S. INDICATIONS AND USAGE POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) ...

Data to be presented in the Immunotherapy & Cell Therapy in Sarcoma: Emerging Frontiers session at the Connective Tissue Oncology Society ...